Related references
Note: Only part of the references are listed.Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis
Elizabeth L. Yanik et al.
CANCER MEDICINE (2015)
Sirolimus Use and Cancer Incidence Among US Kidney Transplant Recipients
E. L. Yanik et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study
K. Budde et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Multivariate and Propensity Score Matching Software with Automated Balance Optimization: TheMatchingPackage forR
Jasjeet S. Sekhon
Journal of Statistical Software (2015)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to Sirolimus
Judith M. Hoogendijk-van den Akker et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler et al.
LANCET (2013)
Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer
S. B. Campbell et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation
L. Mjornstedt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Sylvie Euvrard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients
Eric A. Engels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Skin cancer in solid organ transplant recipients: Advances in therapy and management Part I. Epidemiology of skin cancer in solid organ transplant recipients
Fiona O'Reilly Zwald et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial
Matthew R. Weir et al.
KIDNEY INTERNATIONAL (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne E. Pavel et al.
LANCET (2011)
Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial
Josefina Alberu et al.
TRANSPLANTATION (2011)
Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit
D. Collett et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial
Markus Guba et al.
TRANSPLANTATION (2010)
Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study
Y. Lebranchu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
Francesco P. Schena et al.
TRANSPLANTATION (2009)
mTOR, cancer and transplantation
Edward K. Geissler et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15183 recipients
A. C. Webster et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Kaposi's sarcoma in renal transplant recipients - the impact of proliferation signal inhibitors
Josep M. Campistol et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Immunosuppressive therapy and malignancy in organ transplant recipients - A systematic review
Alex Gutierrez-Dalmau et al.
DRUGS (2007)
Post-transplant de novo malignancies in renal transplant recipients:: the past and present
H. Myron Kauffman et al.
TRANSPLANT INTERNATIONAL (2006)
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
Josep M. Campistol et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies
HM Kauffman et al.
TRANSPLANTATION (2005)
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
G Stallone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies
T Mathew et al.
CLINICAL TRANSPLANTATION (2004)
Cancer after kidney transplantation in the United States
BL Kasiske et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Propensity score-matching methods for nonexperimental causal studies
RH Dehejia et al.
REVIEW OF ECONOMICS AND STATISTICS (2002)
Share Paper
